


EUCAST news


Marina Ivanova EUCAST Eesti esindaja


Tallinn 2013


Implementation of EUCAST breakpoints, January 2013

% Laboratories

 >50%


 10-50%

 <10%


 No information



Countries not on the map:

 Australia

 Iceland

 Israel

2013 uudised



EUCAST

EUROPEAN COMMITTEE
ON ANTIMICROBIAL
SUSCEPTIBILITY TESTING

European Society of Clinical Microbiology and Infectious Diseases

Direct antimicrobial susceptibility testing

Breakpoints modification suggestion 14.10.2013



Proposed modifications to EUCAST clinical breakpoints

Listed below are proposals to modify EUCAST clinical breakpoints. The proposals are open for comment by 15th November 2013. Please send comments, with supporting data or references where appropriate, to the EUCAST Scientific Secretary (derek.brown222@btinternet.com). Please use the attached form for your comments.

Proposal reference	Proposal
1	Amoxicillin-clavulanic acid breakpoints for “uncomplicated UTI only” in addition to existing breakpoints for systemic infections
2	Reduce the doripenem R breakpoint from >4 mg/L to >2 mg/L for Enterobacteriaceae, <i>Pseudomonas</i> spp. and <i>Acinetobacter</i> spp.
3	Removal of the cefaclor breakpoints for <i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i>

AST of *Burkholderia cepacia* complex (BCC)

19.07.2013

Recommendations

While the ISO BMD method may give reproducible MIC results (gradient MIC and disk diffusion methods are not reproducible), it is currently not possible to recommend susceptibility testing of BCC organisms to guide patient therapy.

2012 uudised



European Society of Clinical Microbiology and Infectious Diseases

01.02.2012

Stenotrophomonas maltophilia



European Society of Clinical Microbiology and Infectious Diseases

Why do EUCAST have no systemic breakpoints for Enterobacteriaceae with oral cephalosporins?

16.02.2013



European Society of Clinical Microbiology and Infectious Diseases

Direct antimicrobial susceptibility testing

Tootjate valmidus

- Compliance of manufacturers of AST materials and devices with EUCAST guidelines
- •Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing.
- •The tables will be updated when manufacturers report changes (contact erika.matuschek@ltkronoberg.se).
- •The accuracy of data in these tables is not verified by EUCAST and the inclusion of any materials or devices does not indicate endorsement by EUCAST.
- **Last updated 2013-09-09**

EUCAST koolitus

ESCMID Postgraduate Education Course:

- 16-19 September 2014, Linz, Austria
"Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic - the EUCAST, ESGARS and EPASG Perspective"

ESCMID küsitlus

- **ESCMID Study Group for Molecular Diagnostics - ESGMD**

News & Activities

- **[ESGMD Survey 2013: Survey of current diagnostic methods used in patient management](#)**
- As you know very well from your daily practice, the use of molecular methods for diagnosis and management of patients is commonplace in some areas and still in development in others.
- Our aims with this survey are to
 - investigate the current use of molecular methods
 - estimate access to and usage of guidelines